Impact of tofogliflozin on hepatic outcomes: a systematic review.

Pathak, Mani; Parveen, Rizwana; Khan, Parvej; Saha, Nilanjan; Agarwal, Nidhi

Pathak, Mani; Parveen, Rizwana; Khan, Parvej; Saha, Nilanjan; Agarwal, Nidhi.

Afiliación

Pathak M; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
Parveen R; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
Khan P; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
Saha N; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India.
Agarwal N; Centre for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, 110062, India. nidhi.bharal@gmail.com.

Eur J Clin Pharmacol ; 79(10): 1281-1290, 2023 Oct.

Article en En | MEDLINE | ID: mdl-37462748

Asunto(s)

Diabetes Mellitus Tipo 2; Enfermedad del Hígado Graso no Alcohólico; Humanos; Diabetes Mellitus Tipo 2/tratamiento farmacológico; Hígado/diagnóstico por imagen; Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico; Glucósidos/uso terapéutico; Glucósidos/farmacología; Alanina Transaminasa

Palabras clave

ALT; AST; GGT; MRI-PDFF; Tofogliflozin; Tofogliflozin monohydrate; Type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Eur J Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google